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a b s t r a c t
Dabigatran, a direct thrombin inhibitor and activated factor X inhibitors, rivaroxaban and
apixaban, used in the prevention of stroke or systemic embolism in patients with non-
valvular atrial ﬁbrillation (AF), have several advantages over vitamin K antagonists (VKAs).
The non-vitamin K oral anticoagulants (NOACs) have been shown to reduce the risk of
intracranial bleedings by 50%. The current review summarizes the available data on the
epidemiology, mechanisms and treatment of intracranial bleedings observed on oral antic-
oagulation with the focus on the speciﬁcity of NOACs in this context.
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Atrial ﬁbrillation (AF) is the most common preventable cause
of ischaemic stroke in the general population, with an
increasing prevalence with age from 1% to above 20% at the
age of 80–89 [1]. Strokes associated with AF, which represent
15–20% of all strokes, have a high mortality up to 20–25%
within the ﬁrst 30 days, since the ischaemic event commonly
causes severe neurological deﬁcits [1]. The incidence of
AF-associated stroke decreases by 65% with oral vitamin K* Corresponding author at: Institute of Cardiology, Jagiellonian Univer
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do not receive anticoagulation [2,3]. Although effective, the
major obstacle to the use of VKAs is bleeding complications.
Intracranial bleeding is the most devastating complication of
VKA use, comprising about 8.7% of all major bleeding episodes
and resulting in a 46–55% mortality rate [4].
The anticoagulants, previously termed new oral antic-
oagulants, comprise a thrombin inhibitor, dabigatran, and two
activated factor X (FXa) inhibitors, rivaroxaban and apixaban,
which are approved worldwide for the prevention of stroke
and peripheral embolism in patients with nonvalvular AF [5].sity School of Medicine, 80 Pradnicka St, 31-202 Krakow, Poland.
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Table 1 – Characteristics of target-specific oral anticoagulants (reprinted from Undas A et al. [6] with permission of the
publisher Medycyna Praktyczna).
Variable Warfarin Dabigatran etexilatea Rivaroxaban Apixaban
Mode of action # Synthesis vitamin
K-dependent
coagulation factors
Direct selective and
reversible thrombin
inhibitor
Direct selective and
reversible activated
factor X inhibitor
Direct selective and
reversible activated
factor X inhibitor
Time to peak plasma
concentration
90 min (peak action
after 4–5 d)
0.5–2 h 2–4 h 1–4 h
Half-life 36–42 h 12–14 h 5–9 h (young)
11–13 h (age >65 y)
8–13 h
Substrate of P-glycoprotein
transporter
No Yes Yes Yes
Substrate of CYP enzymes Yes (CYP3A4, CYP2C9) No Yes (CYP3A4/5, CYP2J2) Yes (CYP3A4, CYP2C9)
Route of elimination Variousc 80% renal 66% renal (33% unchanged) 25% renal
Protein binding 99% 35% 90% 90%
Basic daily dose in AF 5 mg (1–18 mg)
Target INR, 2–3
2  150 mg 1  20 mg 2  5 mg
Reduced daily dose Not applicable 2  110 mgb 1  15 mg 2  2.5 mg
Indications for reduced
dosage
Not applicable – CrCl, 30–49 ml/min
– HAS-BLED ≥3 points
– Age ≥80 y
– Coadministration
of verapamil
– CrCl, 30–49 ml/min
– HAS-BLED ≥3 points
– Creatinine ≥133 mM
– Age ≥80 y
– Body weight ≤60 kg
(2 or 3 criteria met)
a A prodrug that undergoes biotransformation to the active molecule, dabigatran, by esterases.
b In the United States: 2  75 mg daily (2  110 mg not approved).
c The anticoagulant effect of warfarin is eliminated through synthesis of functionally active coagulation factors rather than through
elimination of warfarin; coagulation factor synthesis is hastened by exogenous vitamin K.
Abbreviations: INR, international normalized ratio.
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(NOACs) are characterized by rapid onset of action, shorter
half-life, few drug–drug interactions, a predictable anticoagu-
lant response, and no need for routine coagulation monitoring
(Table 1) [6].
The beneﬁts of NOACs in nonvalvular AF have been
documented in large clinical trials (Randomized Evaluation
of Long-Term Anticoagulation Therapy [RELY], Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared With
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation [ROCKET-AF], Apixaban for Reduc-
tion in Stroke and Other Thromboembolic Events in Atrial
Fibrillation [ARISTOTLE]) [7,8]. The use of all the three NOACs
was non-inferior to therapy with VKAs in reducing stroke or
systemic embolism in patients with nonvalvular AF. The
current European Society of Cardiology (ESC) Guidelines on the
Management of AF recommend long-term anticoagulation in
all patients with nonvalvular AF with at least moderate (1
point in the CHA2DS2-VASc score) thromboembolic risk [9]. Of
note, NOACs are a preferred prophylactic option over VKAs in
nonvalvular AF patients [10]. Indirect analysis including 14,527
patients treated with NOACs showed that these anticoagu-
lants were associated with reduced risk of stroke or systemic
embolism (odds ratio [OR], 0.85; 95% CI, 0.74–0.99) compared
with warfarin [11].
2. Characteristics of intracranial bleeding in
patients anticoagulated with NOACs
Large randomized controlled trials [7–9], nationwide cohort
studies in real-world general practice settings in American[12], Asian [13] and European [14] populations have compel-
lingly shown that the use of NOACs in patients with AF results
in markedly fewer intracranial haemorrhagic adverse events
(0.3–0.6 per 100 patient-years) as compared to warfarin. The
reduced risk of intracranial bleeding is one of the major
advantages of these agents over VKAs. There are no direct
head-to-head comparisons of NOACs in this regard. Effective-
ness and safety of all the NOACs approved to clinical use are
supported by several meta-analyses [15–19]. Trials on NOACs
in AF patients have demonstrated that the lowest rate of
intracranial haemorrhage (ICH) as compared to warfarin was
observed for dabigatran at a dose of 110 mg BID, while the
highest rate of ICH and the highest hazard ratio (HR) were
observed for rivaroxaban (Table 2) [7–9]. During dabigatran
treatment with a dose of 150 mg BID intracerebral and
subdural haemorrhages were the most common types of
ICH (46% each), but the rate of subdural haematoma did not
differ from that observed in patients treated with warfarin [the
rate per 100 patient-years was 0.20 vs. 0.31, respectively; HR
(95% CI): 0.65 (0.39–1.1), P < 0.01]. Dabigatran at a dose of
110 mg BID signiﬁcantly reduced the risk of all types of ICH
including traumatic ICH as compared to warfarin [20].
Moreover, the incidence of ICH in subjects treated with
apixaban at a daily dose of 5 mg (2.5 mg BID) is comparable
with that observed in patients treated with aspirin 81–324 mg
daily, so in terms of ICH apixaban seems to be the safest of all
NOACs [21,22]. The absolute rates of fatal intracranial
haemorrhages were lower with dabigatran than with warfarin
[20]. However, there were no differences in fatal ICH between
the treatment with rivaroxaban and warfarin [23]. Such
detailed subanalysis was not performed in trials with apixaban
where the rate of fatal ICH was calculated together with other
Table 2 – The rate of intracranial haemorrhages on NOACs.
Drug Dose Rate of intracranial
haemorrhage (%/year)
Studied drug vs. warfarin
Hazard ratioa
(95% CI)
Rate of haemorrhagic
stroke (%/year)
Studied drug vs. warfarin
Hazard ratioa
(95% CI)
Dabigatran
etexilate
2  110 mg
2  150 mg
0.23 vs. 0.76
0.31 vs. 0.76
0.30 (0.19–0.45); P < 0.001
0.40 (0.27–0.59); P < 0.001
0.12 vs. 0.38
0.10 vs. 0.38
0.31 (0.17–0.56); P < 0.001
0.26 (0.14–0.49); P < 0.001
Rivaroxaban 1  20 mg 0.5 vs. 0.7 0.67 (0.47–0.93); P = 0.02 No data No data
Apixaban 2  5 mg or
2  2.5 mg
0.33 vs. 0.80 0.42 (0.30–0.58); P < 0.001 0.24 vs. 0.47 0.51 (0.35–0.75); P < 0.001
a Hazard ratios are for the NOAC group as compared to the warfarin group.
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analysis to examine the impact of bleeding complications of
NOACs compared with the VKAs in patients with venous
thromboembolism or AF has demonstrated that ICH oc-
curred in 297 of 57,850 (0.51%) patients treated with NOACs
and in 485 of 44,757 (1.08%) patients treated with VKAs in the
12 studies reporting this outcome. NOACs were associated
with a signiﬁcant reduction in intracranial bleeding (RR 0.43
[95% CI, 0.37–0.50], P < 0.01, I2 = 2%). The pooled absolute risk
reduction was 0.57%, resulting in an NNT of 185. Analysis
with a ﬁxed-effects model did not change the results [24].
Direct, well-designed randomized controlled trials would
be needed to specify clinically relevant differences between
individual NOACs. The frequency of intracranial bleeding as a
complication of treatment with NOACs does not depend on
the previous stroke. Such therapy seems to be safe in both
primary and secondary stroke prevention in patients with AF,
although there are only limited data about NOACs for
secondary stroke prevention, since patients in the subacute
phase of stroke and with severe stroke within the past 6
months were excluded from the RE-LY and ROCKET-AF trials
[7–9].
Current recommendations discourage the addition of
aspirin to anticoagulation therapy in most patients with
cardioembolic stroke since there is clear evidence that
combined therapy in AF increases the risk of all bleeding
events [25–28]. The exception to this may represent the
patients with clinically evident coronary artery disease (CAD),
particularly an acute coronary syndrome or those following
implantation of drug-eluting stents. In this group the NOACs
might become an important alternative to VKAs. In the trials
RE-LY, ROCKET-AF and ARISTOTLE 30–40% of patients in the
compared treatment groups were taking aspirin, usually at a
daily dose of less than 100 mg. In the post hoc analysis of the
RE-LY trial, concomitant aspirin use was the key modiﬁable
independent risk factor for ICH but only in patients treated
with warfarin and not in those treated with dabigatran [20].
Further sub-analysis based on the results of the RE-LY trial
conﬁrmed that there were fewer ICH on both doses of
dabigatran than on warfarin, regardless of antiplatelet
treatment. However, one should keep in mind that concomi-
tant treatment with antiplatelet agent(s) leads to a signiﬁcant
rise in the overall risk of major bleeding when combined with
any oral anticoagulant [28]. Such analyses on other NOACs are
not available until now, and dedicated trials are required since
no comparison of combined therapy with antiplatelet drug and
warfarin (or NOACs) to warfarin/NOACs alone has been done
so far, speciﬁcally in stroke populations.There is a paucity of data available to clinically characterize
ICH that occurs on NOACs.
The effect of NOACs on the volume of extravasated blood
and outcome is currently being investigated. An experimental
model of NOAC-associated intracerebral haemorrhage has
been recently developed [29,30]. Unexpectedly, after induction
of intracerebral bleeding by collagenase injection or laser
beam, the volume of extravasated blood did not increase in
dabigatran or rivaroxaban treated mice compared with non-
coagulated controls. Despite haemostasis and prolonged
bleeding time being affected, the therapy had no effect on
functional outcome. Increased volume of extravasated blood
and worse functional outcome were triggered only by very
high doses of the drug resulting in elevated dabigatran plasma
concentrations of up to almost ten times therapeutic values
observed in humans.
Recently the ﬁrst attempts were made to summarize
clinical characteristics of ICH during NOAC treatment. An
analysis of 17 patients who experienced ICH while treated with
dabigatran has been published [31]. In 8 patients stable volume
of extravasated blood as the outcome was reported, but in 3
patients the expansion of ICH resulted in death. In another
study 5 patients with ICH on rivaroxaban have been compared
to those treated with warfarin. As might be expected from
experimental studies, a signiﬁcantly smaller size of extrava-
sated blood was found in subjects on NOACs. Moreover, even
though the patients were at high risk of bleeding (HAS-BLED
score of 3), ICH expansion was not observed in any patient
treated with rivaroxaban, while it occurred in 20% of patients
on warfarin [32]. It may be a result of a favourable limiting
inﬂuence of rivaroxaban on the haematoma enlargement.
Unfortunately, the small number of patients on NOACs is
likely to make the analysis underpowered, the results cited
above are preliminary, and the issue requires further investi-
gation.
3. Potential mechanisms of beneﬁcial effects of
NOACs on intracranial bleeding
The pathomechanism of anticoagulant-associated ICH is not
fully recognized. The major background is impaired haemos-
tasis, but it is unknown whether anticoagulants affect the
integrity of the cerebral vessels. The pathophysiology of
differences between ICH on NOACs vs. warfarin remains
unclear. The presumed mechanism results from the special
local haemostatic conditions within the brain vasculature.
The subendothelial layer of cerebral vessels contains high
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bleeding outside the vessel wall and then into brain
parenchyma result in excessive binding of TF to circulating
activated factor VII (VIIa). It initiates the intrinsic coagulation
pathway by activation of factors IX and X, leading then to the
prothrombinase complex formation [33]. Selective inhibitors
of activated factor X (rivaroxaban, apixaban) and of thrombin
(dabigatran) do not affect the interaction between TF and
factor VIIa, whereas warfarin does so, suppressing the hepatic
production of factor VII. Warfarin that inhibits vitamin K-
dependent gamma-carboxylation of the coagulation factors II,
VII, IX and X reduces their activity in plasma. Thereby it effects
both the initiation and ampliﬁcation of thrombin generation
unpredictably. Therefore the quantity of thrombin that the
coagulation system generates in response to the injury of the
vascular wall is lower during treatment with warfarin than
NOACs, since the latter target only one element of the
coagulation cascade (factor Xa or thrombin) in a stoichiometric
ratio of 1:1 [34]. It might allow for feedback mechanisms within
the coagulation pathway to prevent enlargement of haema-
toma. However, the theory based on the role of TF may be
questioned, since the NOACs reduce the rates of both
intracerebral and subdural haematomas, whereas the patho-
physiology of the latter is different and the role of TF is not so
prominent. One wonders why treatment with another direct
thrombin inhibitor, lepirudin, resulted in haematoma enlarge-
ment in experimental studies. Possible advantages of dabiga-
tran over lepirudin are the result of the selective binding of
dabigatran only to the active site of the thrombin molecule
while two exosites are available for other blood coagulation
proteins. This monovalent binding of dabigatran with throm-
bin inﬂuences only reversible thrombin inhibition. In the
situation of excessive thrombin generation for example
following the vascular wall injury, thrombin inhibition can
be overcome [35].
An interesting observation from experimental studies is
that rivaroxaban and apixaban exert a protective effect on the
neurovascular unit (NVU) after thrombolysis. The interactions
between compounds of NVU as pericytes and astrocytes
through neurotrophins correlate with neuron survival under
hypoxia. Ischaemic injury of pericytes disturbs reﬂow within
the microcirculation and limits delivery of substrates, and the
narrow gap between pericytes and astrocytes is crucial in this
exchange. Unlike the pre-treatment with NOACs, in warfarin
pre-treated rats a marked dissociation between the astrocyte
foot process and pericytes under recombinant tissue plasmin-
ogen activator (r-tPA) treatment was observed. NOACs
dramatically reduce such a complication. This observation
might provide additional explanation for the advantages of
NOACs over warfarin in both ischaemic and haemorrhagic
cerebral lesions [36].
4. Patients at elevated risk of intracranial
bleeding
According to the results of the large trials on NOACs and
warfarin as a comparator, independent predictors of develop-
ing anticoagulant-associated ICH during treatment with novel
anticoagulants were: Asian or Black race, increasing age,uncontrolled hypertension, especially increased diastolic
blood pressure, previous stroke or transient ischaemic attack
(TIA), concomitant use of antiplatelet drugs and reduced
platelet count below 210  109/L. The speciﬁc condition that
increases the risk of intracerebral bleeding during antithrom-
botic treatment is cerebral amyloid angiopathy (CAA) repre-
senting deposition of b-amyloid within the wall of the cerebral
small vessels. Even beside the antithrombotic treatment, CAA
results in symptomatic intracerebral haemorrhage and
asymptomatic cerebral microbleeds (CMBs). The CMBs corre-
spond to the deposits of hemosiderin located around sclerotic
vessels, and their prevalence increases with age. They are
associated with lesions below 10 mm in diameter detected
with special sequences of magnetic resonance imaging (MRI)
as T2 gradient-recall echo (GRE) and susceptibility-weighted
imaging (SWI) sequences. There are two typical locations of
CMBs, deep subcortical and infratentorial, which correspond
to vascular disease, in particular hypertension, and lobar
disease, associated with apolipoprotein E (ApoE) e2/e4 geno-
type carrier and CAA conﬁrmed in an autopsy. Patients with
ischaemic stroke or TIA and with CMBs are as much as three
times more likely to have either haemorrhagic transformation
of ischaemic lesions or recurrent haemorrhagic stroke [37–40].
The risk of fatal intracerebral haemorrhage increases with the
number of CMBs. Two-year risk of intracerebral bleeding is
calculated as 8% if more than 5 CMBs are present. In a meta-
analysis of antithrombotic treatment, CMBs were more
common in patients on warfarin or antiplatelet agents and
with intracerebral haemorrhage than in those with ischaemic
stroke or TIA. Thus in patients with multiple CMBs the risk of
fatal ICH may even outweigh the beneﬁts of antithrombotic
therapy [41,42]. The risk of ICH in patients treated with NOAC
and burdened with CMBs remains to be clariﬁed. The novel
antithrombotic therapy may be beneﬁcial in this group of
patients, but there are insufﬁcient data to mandate changes in
the previously chosen drug regimen only because of CMBs. The
irreversibility of the NOACs and lack of antidotes in setting of a
putative ICH supports such a cautious approach.
The risk of ICH might be stratiﬁed according to the useful
CHADS2, CHA2DS2-VASc and HAS-BLED scales. The risk of ICH
on dabigatran increased with higher CHADS2 scores, while in
patients on apixaban the rate of ICH was lower in patients with
high CHADS2 scores compared to those with lower scores, and
relative ICH risk reduction tended to be greater in patients with
HAS-BLED scores of 3 or more as compared to warfarin [43].
5. Treatment of ICH on NOACs
There is no speciﬁc antidote available for any of the NOACs,
and clinical experience with haemostatic agents in NOAC-
associated bleeding is scarce. Therefore, nonspeciﬁc reversal
therapies may be considered based on available, but limited,
evidence [44,45]. Use of either agent is based on poor-quality
data and as such should not be considered a requirement in
the setting of intracranial bleeding. The therapeutic options
presented below are based on the experts' opinion, while the
manufacturers' recommendations from the product charac-
teristics are very limited and mainly apply the overdosage of
NOACs.
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Soon after ingestion, the absorption of lipophilic dabigatran
may be reduced by gastric lavage and/or administration of
charcoal. Activated prothrombin complex concentrate (aPCC)
(80 U/kg) is slightly preferred over 3-factor (FII, IX, X)
prothrombin complex concentrate (PCC), or 4-factor (FII, VII,
IX, X) PCC, because it may improve hemostasis, probably by
providing small amounts of thrombin. Alternative agents,
such as recombinant activated factor VII (rVIIa), have not been
demonstrated to reverse bleeding on dabogatran. Dabigatran,
which is in only 35% bound to plasma proteins, can be
removed by hemodialysis; 49–68% of active dabigatran can be
removed after 4 h of hemodialysis in patients with end-stage
renal disease. Duration of dialysis appears to have the greatest
impact on dabigatran plasma concentrations [46]. In a recent
case series, plasma dabigatran levels were reduced by 52–77%
in 5 dabigatran-treated patients with life-threatening bleeding
following treatment with hemodialysis. Three of the 5 patients
experienced rebound increases in dabigatran concentration
following hemodialysis, likely related to drug redistribution
from the extravascular compartment [45].
5.2. Rivaroxaban and apixaban
Because of a high degree of albumin binding in plasma,
rivaroxaban and apixaban are not dialyzable. Charcoal
hemoperfusion removes highly protein bound drugs, but, to
our knowledge, there are no studies assessing the removal of
rivaroxaban or apixaban with hemodialysis or charcoal
hemoperfusion. All measurable anticoagulant effects of these
drugs are reversed by 4-factor PCC, as studied in healthy
volunteers [47]. Clinical data are still lacking, but it seems
reasonable to administer a dose of 50 IU/kg or a standard dose
of 2000 IU in case of ICH. It is unknown whether this needs to
be repeated and whether 3-factor PCC is effective for reversal
of rivaroxaban.
5.3. Adjunctive hemostatic therapies
There have been no studies evaluating the efﬁcacy and safety
of desmopressin (1-desamino-8-D-arginine vasopressin) in the
context of NOAC-associated bleeding. Because desmopressin
promotes release of von Willebrand factor from endothelial
cells, it is biologically plausible (although unproven) that
desmopressin could be of beneﬁt to a patient with NOAC-
associated bleeding. If repeated doses are given, close
monitoring of serum electrolytes is required due to the
potential for hyponatremia.
Tranexamic acid stabilizes ﬁbrin clots by interfering with
ﬁbrinolysis and can also be used as adjunctive therapy for
severe bleeding in a variety of circumstances. Its hemostatic
efﬁcacy in the setting of NOAC-associated bleeding is
unknown.
5.4. Speciﬁc antidotes
Several antidotes for the NOACs are in clinical development.
Andexanet alfa (a recombinant FXa derivative lacking catalytic
and membrane-binding activity) is a modiﬁed factor Xamolecule used to directly reverse effects of apixaban,
rivaroxaban, and edoxaban. It binds the anticoagulant drug,
thus making the patient's own factor Xa molecule available to
participate in blood coagulation. A phase III study (ANNEXA-R)
testing the safety and efﬁcacy of the antidote recently reached
its primary end point. In this trial, an 800-mg intravenous
bolus of andexanet alfa, which was tested in 41 healthy
volunteers treated with rivaroxaban 20 mg for 4 days and then
subsequently randomized to the study drug or placebo,
‘‘immediately and signiﬁcantly’’ reversed the steady-state
anticoagulation activity of rivaroxaban. Idarucizumab (aDabi-
Fab) is a humanized mouse monoclonal antibody fragment
directed against dabigatran. A phase III study of patients on
dabigatran with major bleeding or needing emergency surgery
is under way. Aripazine is a small synthetic molecule (a D-
arginine compound) that appears to have broad activity
against dabigatran, rivaroxaban, apixaban, edoxaban, and
heparins. A ﬁrst study investigating the drug's effect on
edoxaban-treated human volunteers has been completed [48].
6. The use of antithrombotic therapy in
patients with a prior ICH
The use of antithrombotic therapies to prevent thromboem-
bolism in patients with an acute or prior ICH presents a clinical
dilemma with competing risks and beneﬁts. In many cases,
clinical decisions must be made on the basis of indirect and
observational evidence rather than high quality clinical trials.
In the absence of randomized controlled trials to address these
treatment dilemmas, the European Stroke Organization did
not make ﬁrm recommendations about whether and when to
resume antithrombotic drugs after intracranial haemorrhage
[44]. Suggested timings for restarting these drugs range from
not earlier than 14 days up to 10 to 30 weeks. Left atrial
appendage occlusion could be an alternative for managing
patients in AF with a high risk of cardioembolic stroke after
acute ICH [49].
It is important to prevent deep vein thrombosis (DVT) and/
or pulmonary embolism (PE) in patients with ICH. In immobile
patients with ICH intermittent pneumatic compression (IPC)
has been shown to improve outcome and reduce the risk of
DVT. In the CLOTS-3 trial comparing IPC vs. no IPC for
immobile patients with stroke, IPC was superior for the
prevention of the primary outcome of proximal DVT within 30
days (8.5% vs. 12.1%; OR 0.65, 95% CI 0.51–0.84; P = 0.001),
patients with ICH seemed to beneﬁt at least as much as
patients with ischaemic stroke (OR 0.36, 95% CI 0.17–0.75 vs. OR
0.72, 95% CI 0.55–0.93; P = 0.057), and IPC may be superior for
the prevention of death within six months (adjusted HR 0.86,
95% CI 0.74–0.99; P = 0.042) [50]. There is insufﬁcient evidence
from randomized controlled trials to make strong recommen-
dations about how, when, and for whom anticoagulation
should be given to prevent DVT or improve outcome [44]. The
latest Antithrombotic Therapy and Prevention of Thrombosis
American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines and Polish Guidelines of Prophylaxis and
Treatment of Venous Thromboembolism published in 2012
suggested that if thrombotic risk persists, pharmacologic
thromboprophylaxis using subcutaneous low-molecular-
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mechanical thromboprophylaxis in patients with ICH, starting
on day 2–4 after bleeding, if there are no signs of haematoma
expansion [51,52].
7. Laboratory monitoring during therapy with
NOACs
It is well known that the use of NOACs eliminates the need for
routine laboratory monitoring. A major clinical situation in
which laboratory monitoring of NOACs could be considered is
life-threatening bleeding, in particular ICH. Other potential
indications to determine blood concentrations of NOACs
include: the exclusion of persistent anticoagulant effects
before surgery or an invasive procedure when the patient
has taken the drug in the previous 24 h, or longer if creatinine
clearance is reduced; identiﬁcation of sub-or supra-therapeu-
tic levels in patients taking other drugs that are known to
signiﬁcantly affect pharmacokinetics or those at extremes of
body weight; reversal of anticoagulation; suspicion of over-
dose; and ﬁnally, assessment of compliance in patients
suffering thrombotic events whilst on treatment [6,53,54].
A method for the precise measurement of circulating levels
of NOACs used in several trials is liquid chromatography–
tandem mass spectrometry (LC–MS/MS). In clinical practice
the dilute thrombin time (TT) for dabigatran or anti-Xa activity
for rivaroxaban or apixaban, using the appropriate calibrators
(not those used to monitor low-molecular-weight heparins), is
used. These coagulometric tests provide results that well
correlate with the values obtained using LC–MS/MS [55,56]. It
has already been recommended using the TT-based assay to
rather accurately estimate concentrations of dabigatran
>50 ng/ml [55].
NOACs may alter routine coagulation tests within the ﬁrst
hours following drug intake in most subjects. Within the ﬁrst
2–8 h after intake of dabigatran, depending on renal function
and the analyzer and reagent used to perform the test, the
activated partial thromboplastin time (aPTT) may be pro-
longed to between 40 and 60 s, with a linear relationship with
dabigatran concentrations up to 200 ng/ml. In patients treated
with dabigatran, TT is prolonged at low concentrations and
exceeds the upper limit of the reference range as plasma levels
rise. A normal TT excludes signiﬁcant plasma concentrations
of dabigatran, which is in stark contrast to rivaroxaban and
apixaban, which do not prolong the TT. In patients receiving
rivaroxaban, prothrombin time (PT) values are often elevated
above the upper limit of the reference range, leading to an
increased international normalized ratio (INR) calculated by
most automatic analyzers. Of note, results of routine labora-
tory tests determined after administration of NOACs display
substantial differences that largely depend on the thrombo-
plastin or PT reagents used to perform the tests. Routine
coagulation tests cannot be used to monitor NOACs. In
addition, NOACs may interfere with other clot-based tests
such as clotting factor levels, antithrombin (false normal
results in deﬁcient patients on dabigatran in a thrombin-based
assay), protein C (false normal results in deﬁcient patients on
dabigatran), lupus anticoagulant (false positive results in some
patients at peak plasma concentrations of drug and a majorityof patients on rivaroxaban with no consistent effect of
apixaban), thrombin generation, thromboelastography and
others [53–56]. Importantly, the effects of NOACs on anti-
thrombin, protein C and protein S assays were dependent on
the type of reagent. Measurements of plasma D-dimer
concentrations are unaffected by NOACs.
The ﬁrst Polish experience with the use of the HEMOCLOT
assay to measure dabigatran concentrations that has been
approved for clinical use in Europe, as well as that of calibrated
chromogenic factor Xa assays, has been recently published
[57,58].
To interpret the results of the tests, the exact time of the
blood sample acquisition relative to the intake of the last dose
of NOACs is of key importance. Renal function assessment is
also helpful [48]. Until now, ‘‘cut-off points’’ between which
anticoagulation with NOACs is therapeutic (the equivalent of
the therapeutic range known for VKA) have not been deﬁned
[59]. In the case of ICH or other severe bleeding, plasma levels
of dabigatran and rivaroxaban above 50 ng/ml strongly suggest
detectable anticoagulant effects, which indicates that the
complication is likely associated with the agents. This result
could be useful when it is unclear when the patients with ICH
have taken the last dose of NOACs.
Ischaemic stroke treated with thrombolysis is another
speciﬁc clinical situation when knowledge on the coagulation
status and plasma concentration of NOAC is required.
Thrombolytic treatment is allowed in subjects anticoagulated
with vitamin K antagonists when INR is below 1.7 [60].
However, in patients treated with NOACs no decision-making
model has been developed, and reports on such treatment are
limited to case studies. Recently Kate et al. proposed a
thrombolysis protocol for acute ischaemic stroke in patients
taking dabigatran. The authors presumed conservative but
arbitrary thresholds for dabigatran plasma concentrations
(below 10 ng/ml), TT (<38 s) and aPTT (<37 s) as the inclusion
criteria [61]. However, some investigators reported that the
decision-making process should not b based on routine
coagulation markers in stroke patients. Folyovich et al.
reported a case of doubling of both TT and aPTT within 5
days after stroke in patients pretreated with dabigatran and
without any change in anticoagulant treatment after an
ischaemic event [62]. Since the number of patients antic-
oagulated with NOACs continues to grow, there is a need to
develop a speciﬁc approach in this clinical setting.
Taken together, laboratory monitoring of NOACs should be
implemented in reference centres taking care of patients with
stroke as well as those with ICH.
8. Conclusions
In conclusion, the rate of ICH in patients with AF treated with
NOACs is signiﬁcantly lower as compared to warfarin.
Experimental and clinical studies suggest that NOACs might
have a less detrimental effect on ICH outcome than warfarin.
Intracranial haemorrhage on NOACs seems to be character-
ized by lower volume and smaller expansion. The strongest
risk factors for ICH to be considered before a decision on the
management are as follows: older age, greater number of CMBs
in MRI, presence of ApoE e2/e4 genotype and concomitant
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 7 1 – 1 7 9 177treatment with antiplatelet drugs. Increasing use of NOACs
worldwide is likely to lower the incidence of the most
dangerous complication of long-term anticoagulation and
thus improving the safety of ischaemic stroke prevention
administered in the right patients at the right time.
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